CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. "In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease
<i>-HCV: Rolling submission of New Drug Application for telaprevir
expected to begin in summer of 2010; first Phase 3 SVR data expected in
second quarter 2010 from ADVANCE trial-</i>
<br />
<i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of
Phase 3 registration program for VX-770; data expected in first half of
2011-</i>
<br />
<i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical
trials with compounds for rheumatoid arthritis and epilepsy and with
novel combination regimens for HCV and CF-</i>
<br />
<i>-Financial: Vertex ends first quarter with cash position of
approximately $1.1 billion-</i>
<br />
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.
Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was
- VX-950 Global Phase 2b Clinical Development Plan On Track -<br>
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company,
Adds Important Strengths<br>
and Development Capabilities for VX-950 -
CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first
<i>- Telaprevir Phase 3 registration program in hepatitis C on track;
NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying
disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash
equivalents and marketable securities; Vertex will add to this position
with $105 million of cash through an amended agreement with Mitsubishi
Tanabe Pharma Corporation -</i><br />
<i>-Hepatitis C: Rolling submission of New Drug Application underway;
data from second pivotal Phase 3 trial - REALIZE - expected in the third
quarter of 2010-</i>
<br />
<i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully
enrolled; data expected in first half of 2011-</i>
<br />
<i>-Financial: Vertex ends second quarter with cash position of
approximately $980 million-</i>
<br />
Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD Additional compounds for HCV and Cystic Fibrosis scheduled to enter development Cambridge, MA, October 29, 2007 Vertex
<i>-Phase 3 registration programs in hepatitis C and cystic fibrosis on
track-</i><br /><i>-Vertex to present telaprevir SVR data from Study C208 at AASLD
meeting this week-</i><br />
<i>-Hepatitis C:</i> <i>New Drug Application submission for telaprevir
on track for fourth quarter 2010-</i>
<br />
<i>-Cystic Fibrosis:</i> <i>Phase 3 registration program ongoing for
VX-770-</i>
<br />
<i>-Pipeline:</i> <i>Ongoing proof-of-concept clinical trials in
hepatitis C, cystic fibrosis, epilepsy and rheumatoid arthritis-</i>
<br />
<i>-Financial:</i> <i>Company ends third quarter with a cash position of
$1.2 billion-</i>
<br />
--Telaprevir data in HCV patients who failed current therapies to<br> be presented at EASL--<br><br> --Pharmacokinetic analyses in HCV patients show potential for<br> twice-daily dosing of telaprevir--<br><br> --VX-770 for cystic fibrosis to advance based on positive results<br> reported in March 2008--
<i>- Telaprevir registration program on track; VCH-222 enters
multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D
mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash
equivalents and marketable securities-</i>
CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors
<i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock
transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have
demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009
start -</i>
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>
CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes
First HCV protease inhibitor in pivotal trial for this difficult<br> to treat patient population<br><br> Trial to enroll all major treatment-failure patient groups,<br> including null responders, partial responders and relapsers<br><br> Two telaprevir registration programs to address significant unmet<br> need in treatment-naive and treatment-failure patients
Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive
Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005
Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.
-Interim results of largest real-world study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction in pulmonary exacerbations frequency and lower rates of lung transplant and death for people with cystic fibrosis- - Twelve
- 12 abstracts presented at 30 th Annual North American Cystic Fibrosis Conference highlight data from Vertex's CF program - ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ®
– Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 – – Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%
- New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from a Phase 3
– All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use – – The two patients with at least one year of follow-up met the criteria for the primary endpoint of elimination of
- All patients treated with VX-880 in Parts A and B have follow-up data beyond Day 90 and have demonstrated islet cell engraftment and glucose-responsive insulin production - - All patients showed improvement across all measures of glucose control, including decreases in HbA1c, increases in blood
CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of
BOSTON --(BUSINESS WIRE)--Jan. 7, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January
-Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI
- Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 - - AATD research program continues to progress - BOSTON --(BUSINESS
-U.S. Study: FDA places partial clinical hold on ongoing Phase 2 U.S. study of VX-135, preventing evaluation of 200 mg dose following observation of elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in Phase 2 study in Europe ; evaluation of 100 mg dose
-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation-
-Two-drug treatment arm of telaprevir and VX-222 alone discontinued- -Study continues with three arms, including all-oral combination of Vertex's lead protease and polymerase inhibitors with ribavirin- -Both of the four-drug treatment arms are fully enrolled; the majority of patients in these arms
- PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.